A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
Nicole J. Ullrich(Boston Children's Hospital), Mark W. Kieran(Children Cancer Hospital), Bruce R. Korf(University of Alabama at Birmingham), Alan Cantor(Cincinnati Children's Hospital Medical Center), Nathan Robison(University of Southern California), Roger J. Packer(Children's Hospital of Philadelphia), Peter Manley(Boston Children's Hospital), Sanjay P. Prabhu(Boston Children's Hospital), Alyssa Reddy, Coretta Thomas(University of Alabama), Gary Cutter(Epilepsy Foundation), David Viskochil(University of Utah), Alexander A. Vinks(Cincinnati Children's Hospital Medical Center), David H. Gutmann(Washington University in St. Louis), Susan Chi(Harvard University), Stewart Goldman(St Nicholas Hospital), John P. Perentesis(University of Southern California), Michael J. Fisher(Children's Hospital of Philadelphia), Jeffrey C. Allen(Eglin Air Force Base), Tomoyuki Mizuno(Cincinnati Children's Hospital Medical Center)
Cited by 82
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
|Cell|1990|1.1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766